No, it is the question because countries with public health systems often don’t pay for the latest generation of drugs, since they don’t feel the extra cost is worth the benefit.
Just repeating the question, when I gave you the answer, isn't very productive.
We should ask what are the outcomes that these systems produce, not how new the drugs are.
A cutting-edge healthcare system plagued by inequality and extreme costs can produce worse results than a more efficient healthcare system which is not as high-tech.
But yes, I agree. Sometimes the juice isn’t worth the squeeze.